Do analysts recommend ORMP or IRWD?

Ironwood Pharmaceuticals has a consensus target price of $6.23, indicating a potential upside of 46.84%. Given Ironwood Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Ironwood Pharmaceuticals is more favorable than Oramed Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oramed Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Ironwood Pharmaceuticals 0 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.57

Does the media prefer ORMP or IRWD?

In the previous week, Ironwood Pharmaceuticals had 4 more articles in the media than Oramed Pharmaceuticals. MarketBeat recorded 8 mentions for Ironwood Pharmaceuticals and 4 mentions for Oramed Pharmaceuticals. Ironwood Pharmaceuticals' average media sentiment score of 0.85 beat Oramed Pharmaceuticals' score of -0.02 indicating that Ironwood Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oramed Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ironwood Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate ORMP or SVA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oramed Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Sinovac Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better valuation and earnings, ORMP or SVA?

Oramed Pharmaceuticals has higher earnings, but lower revenue than Sinovac Biotech. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Oramed Pharmaceuticals $2M 91.52 $64.05M $4.12 1.07 Sinovac Biotech $386.01M 0.96 -$59.68M N/A N/A

Is ORMP or SVA more profitable?

Sinovac Biotech's return on equity of 0.00% beat Oramed Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Oramed Pharmaceuticals N/A -5.80% -5.16% Sinovac Biotech N/A N/A N/A

Does the media refer more to ORMP or SVA?

In the previous week, Oramed Pharmaceuticals had 2 more articles in the media than Sinovac Biotech. MarketBeat recorded 4 mentions for Oramed Pharmaceuticals and 2 mentions for Sinovac Biotech. Sinovac Biotech's average media sentiment score of 0.93 beat Oramed Pharmaceuticals' score of -0.02 indicating that Sinovac Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oramed Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sinovac Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer ORMP or CBIO?

Crescent Biopharma has a consensus target price of $29.40, suggesting a potential upside of 71.98%. Given Crescent Biopharma's stronger consensus rating and higher possible upside, analysts plainly believe Crescent Biopharma is more favorable than Oramed Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oramed Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Crescent Biopharma 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.60

Is ORMP or CBIO more profitable?

Oramed Pharmaceuticals' return on equity of -5.80% beat Crescent Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Oramed Pharmaceuticals N/A -5.80% -5.16% Crescent Biopharma N/A -101.50% -86.86%

Does the media refer more to ORMP or CBIO?

In the previous week, Oramed Pharmaceuticals had 2 more articles in the media than Crescent Biopharma. MarketBeat recorded 4 mentions for Oramed Pharmaceuticals and 2 mentions for Crescent Biopharma. Crescent Biopharma's average media sentiment score of 0.79 beat Oramed Pharmaceuticals' score of -0.02 indicating that Crescent Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oramed Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Crescent Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend TECX or ORMP?

Tectonic Therapeutic presently has a consensus price target of $77.80, indicating a potential upside of 124.82%. Given Tectonic Therapeutic's stronger consensus rating and higher possible upside, research analysts clearly believe Tectonic Therapeutic is more favorable than Oramed Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tectonic Therapeutic 2 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 2.75 Oramed Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is TECX or ORMP more profitable?

Oramed Pharmaceuticals' return on equity of -5.80% beat Tectonic Therapeutic's return on equity. Company Net Margins Return on Equity Return on Assets Tectonic Therapeutic N/A -34.35% -32.80% Oramed Pharmaceuticals N/A -5.80% -5.16%

Does the media prefer TECX or ORMP?

In the previous week, Tectonic Therapeutic had 4 more articles in the media than Oramed Pharmaceuticals. MarketBeat recorded 8 mentions for Tectonic Therapeutic and 4 mentions for Oramed Pharmaceuticals. Tectonic Therapeutic's average media sentiment score of 0.31 beat Oramed Pharmaceuticals' score of -0.02 indicating that Tectonic Therapeutic is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tectonic Therapeutic 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Oramed Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate ORMP or AVTE?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oramed Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Aerovate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is ORMP or AVTE more profitable?

Oramed Pharmaceuticals' return on equity of -5.80% beat Aerovate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Oramed Pharmaceuticals N/A -5.80% -5.16% Aerovate Therapeutics N/A -90.19% -77.47%

Oramed Pharmaceuticals (ORMP) Competitors

$4.40 +0.02 (+0.46%)

As of 01:30 PM Eastern

Compare

ORMP vs. IRWD, SVA, CBIO, TECX, and AVTE

Should you buy Oramed Pharmaceuticals stock or one of its competitors? Oramed Pharmaceuticals's main competitors and comparable companies include Ironwood Pharmaceuticals (IRWD), Sinovac Biotech (SVA), Crescent Biopharma (CBIO), Tectonic Therapeutic (TECX), and Aerovate Therapeutics (AVTE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Oramed Pharmaceuticals compare to Ironwood Pharmaceuticals?

Oramed Pharmaceuticals (NASDAQ:ORMP) and Ironwood Pharmaceuticals (NASDAQ:IRWD) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations, media sentiment and risk.

Ironwood Pharmaceuticals has a net margin of 33.36% compared to Oramed Pharmaceuticals' net margin of 0.00%. Oramed Pharmaceuticals' return on equity of -5.80% beat Ironwood Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oramed Pharmaceuticals	N/A	-5.80%	-5.16%
Ironwood Pharmaceuticals	33.36%	-58.38%	34.93%

12.7% of Oramed Pharmaceuticals shares are owned by institutional investors. 20.8% of Oramed Pharmaceuticals shares are owned by insiders. Comparatively, 9.3% of Ironwood Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Oramed Pharmaceuticals has a beta of 1.22, suggesting that its share price is 22% more volatile than the broader market. Comparatively, Ironwood Pharmaceuticals has a beta of 0.2, suggesting that its share price is 80% less volatile than the broader market.

Oramed Pharmaceuticals has higher earnings, but lower revenue than Ironwood Pharmaceuticals. Oramed Pharmaceuticals is trading at a lower price-to-earnings ratio than Ironwood Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oramed Pharmaceuticals	$2M	91.52	$64.05M	$4.12	1.07
Ironwood Pharmaceuticals	$389.32M	1.78	$24.02M	$0.77	5.51

In the previous week, Ironwood Pharmaceuticals had 4 more articles in the media than Oramed Pharmaceuticals. MarketBeat recorded 8 mentions for Ironwood Pharmaceuticals and 4 mentions for Oramed Pharmaceuticals. Ironwood Pharmaceuticals' average media sentiment score of 0.85 beat Oramed Pharmaceuticals' score of -0.02 indicating that Ironwood Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oramed Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ironwood Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Ironwood Pharmaceuticals has a consensus target price of $6.23, indicating a potential upside of 46.84%. Given Ironwood Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Ironwood Pharmaceuticals is more favorable than Oramed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oramed Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Ironwood Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.57

Summary

Ironwood Pharmaceuticals beats Oramed Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Oramed Pharmaceuticals compare to Sinovac Biotech?

Oramed Pharmaceuticals (NASDAQ:ORMP) and Sinovac Biotech (NASDAQ:SVA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, analyst recommendations, earnings, media sentiment and risk.

Oramed Pharmaceuticals has higher earnings, but lower revenue than Sinovac Biotech.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oramed Pharmaceuticals	$2M	91.52	$64.05M	$4.12	1.07
Sinovac Biotech	$386.01M	0.96	-$59.68M	N/A	N/A

Oramed Pharmaceuticals has a beta of 1.22, meaning that its share price is 22% more volatile than the broader market. Comparatively, Sinovac Biotech has a beta of 0.35, meaning that its share price is 65% less volatile than the broader market.

12.7% of Oramed Pharmaceuticals shares are held by institutional investors. 20.8% of Oramed Pharmaceuticals shares are held by insiders. Comparatively, 12.8% of Sinovac Biotech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Sinovac Biotech's return on equity of 0.00% beat Oramed Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oramed Pharmaceuticals	N/A	-5.80%	-5.16%
Sinovac Biotech	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oramed Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Sinovac Biotech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Oramed Pharmaceuticals had 2 more articles in the media than Sinovac Biotech. MarketBeat recorded 4 mentions for Oramed Pharmaceuticals and 2 mentions for Sinovac Biotech. Sinovac Biotech's average media sentiment score of 0.93 beat Oramed Pharmaceuticals' score of -0.02 indicating that Sinovac Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oramed Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sinovac Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Oramed Pharmaceuticals beats Sinovac Biotech on 7 of the 11 factors compared between the two stocks.

How does Oramed Pharmaceuticals compare to Crescent Biopharma?

Oramed Pharmaceuticals (NASDAQ:ORMP) and Crescent Biopharma (NASDAQ:CBIO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and media sentiment.

Crescent Biopharma has a consensus target price of $29.40, suggesting a potential upside of 71.98%. Given Crescent Biopharma's stronger consensus rating and higher possible upside, analysts plainly believe Crescent Biopharma is more favorable than Oramed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oramed Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Crescent Biopharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

12.7% of Oramed Pharmaceuticals shares are held by institutional investors. Comparatively, 75.2% of Crescent Biopharma shares are held by institutional investors. 20.8% of Oramed Pharmaceuticals shares are held by insiders. Comparatively, 24.8% of Crescent Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Oramed Pharmaceuticals' return on equity of -5.80% beat Crescent Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oramed Pharmaceuticals	N/A	-5.80%	-5.16%
Crescent Biopharma	N/A	-101.50%	-86.86%

In the previous week, Oramed Pharmaceuticals had 2 more articles in the media than Crescent Biopharma. MarketBeat recorded 4 mentions for Oramed Pharmaceuticals and 2 mentions for Crescent Biopharma. Crescent Biopharma's average media sentiment score of 0.79 beat Oramed Pharmaceuticals' score of -0.02 indicating that Crescent Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oramed Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Crescent Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Oramed Pharmaceuticals has higher earnings, but lower revenue than Crescent Biopharma. Crescent Biopharma is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oramed Pharmaceuticals	$2M	91.52	$64.05M	$4.12	1.07
Crescent Biopharma	$10.84M	58.57	-$153.94M	-$6.72	N/A

Oramed Pharmaceuticals has a beta of 1.22, suggesting that its stock price is 22% more volatile than the broader market. Comparatively, Crescent Biopharma has a beta of 1.23, suggesting that its stock price is 23% more volatile than the broader market.

Summary

Crescent Biopharma beats Oramed Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Oramed Pharmaceuticals compare to Tectonic Therapeutic?

Tectonic Therapeutic (NASDAQ:TECX) and Oramed Pharmaceuticals (NASDAQ:ORMP) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, media sentiment, profitability, earnings and institutional ownership.

Oramed Pharmaceuticals has higher revenue and earnings than Tectonic Therapeutic. Tectonic Therapeutic is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tectonic Therapeutic	N/A	N/A	-$74.15M	-$4.57	N/A
Oramed Pharmaceuticals	$2M	91.52	$64.05M	$4.12	1.07

62.6% of Tectonic Therapeutic shares are held by institutional investors. Comparatively, 12.7% of Oramed Pharmaceuticals shares are held by institutional investors. 39.8% of Tectonic Therapeutic shares are held by insiders. Comparatively, 20.8% of Oramed Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Tectonic Therapeutic has a beta of 3.28, indicating that its stock price is 228% more volatile than the broader market. Comparatively, Oramed Pharmaceuticals has a beta of 1.22, indicating that its stock price is 22% more volatile than the broader market.

In the previous week, Tectonic Therapeutic had 4 more articles in the media than Oramed Pharmaceuticals. MarketBeat recorded 8 mentions for Tectonic Therapeutic and 4 mentions for Oramed Pharmaceuticals. Tectonic Therapeutic's average media sentiment score of 0.31 beat Oramed Pharmaceuticals' score of -0.02 indicating that Tectonic Therapeutic is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tectonic Therapeutic	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Oramed Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Oramed Pharmaceuticals' return on equity of -5.80% beat Tectonic Therapeutic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tectonic Therapeutic	N/A	-34.35%	-32.80%
Oramed Pharmaceuticals	N/A	-5.80%	-5.16%

Tectonic Therapeutic presently has a consensus price target of $77.80, indicating a potential upside of 124.82%. Given Tectonic Therapeutic's stronger consensus rating and higher possible upside, research analysts clearly believe Tectonic Therapeutic is more favorable than Oramed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tectonic Therapeutic	2 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.75
Oramed Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Tectonic Therapeutic beats Oramed Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Oramed Pharmaceuticals compare to Aerovate Therapeutics?

Oramed Pharmaceuticals (NASDAQ:ORMP) and Aerovate Therapeutics (NASDAQ:AVTE) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, media sentiment, risk and analyst recommendations.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oramed Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Aerovate Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

12.7% of Oramed Pharmaceuticals shares are held by institutional investors. 20.8% of Oramed Pharmaceuticals shares are held by company insiders. Comparatively, 24.9% of Aerovate Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Oramed Pharmaceuticals had 4 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 4 mentions for Oramed Pharmaceuticals and 0 mentions for Aerovate Therapeutics. Aerovate Therapeutics' average media sentiment score of 0.00 beat Oramed Pharmaceuticals' score of -0.02 indicating that Aerovate Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Oramed Pharmaceuticals	Neutral
Aerovate Therapeutics	Neutral

Oramed Pharmaceuticals' return on equity of -5.80% beat Aerovate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oramed Pharmaceuticals	N/A	-5.80%	-5.16%
Aerovate Therapeutics	N/A	-90.19%	-77.47%

Oramed Pharmaceuticals has higher revenue and earnings than Aerovate Therapeutics. Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oramed Pharmaceuticals	$2M	91.52	$64.05M	$4.12	1.07
Aerovate Therapeutics	N/A	N/A	-$75.52M	-$1.70	N/A

Oramed Pharmaceuticals has a beta of 1.22, suggesting that its share price is 22% more volatile than the broader market. Comparatively, Aerovate Therapeutics has a beta of 0.95, suggesting that its share price is 5% less volatile than the broader market.

Summary

Oramed Pharmaceuticals beats Aerovate Therapeutics on 10 of the 12 factors compared between the two stocks.

Get Oramed Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ORMP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ORMP vs. The Competition

Export

Metric	Oramed Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$183.04M	$3.70B	$6.98B	$13.02B
Dividend Yield	5.85%	3.76%	2.58%	10.72%
P/E Ratio	1.07	10.38	269.27	25.25
Price / Sales	91.52	1,292.94	597.31	101.05
Price / Cash	47.07	103.01	70.53	50.75
Price / Book	0.88	17.48	13.07	6.33
Net Income	$64.05M	-$13.32M	$3.45B	$347.81M
7 Day Performance	2.33%	0.94%	0.74%	0.90%
1 Month Performance	10.00%	0.76%	1.40%	0.89%
1 Year Performance	107.55%	54.88%	67.03%	20.36%

Oramed Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ORMP Oramed Pharmaceuticals	1.6831 of 5 stars	$4.40 +0.5%	N/A	+106.6%	$183.04M	$2M	1.07	10	Earnings Report
IRWD Ironwood Pharmaceuticals	3.1532 of 5 stars	$4.30 +6.2%	$6.23 +45.0%	+274.3%	$660.39M	$296.15M	5.58	220
SVA Sinovac Biotech	0.9367 of 5 stars	$6.47 flat	N/A	N/A	$644.66M	$386.01M	N/A	3,008	News Coverage High Trading Volume
CBIO Crescent Biopharma	3.1573 of 5 stars	$16.69 -3.7%	$29.40 +76.2%	+19.6%	$643.70M	$10.84M	N/A	50
TECX Tectonic Therapeutic	2.9978 of 5 stars	$31.87 -2.6%	$77.80 +144.1%	+53.8%	$639.46M	N/A	N/A	120

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ORMP) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Oramed Pharmaceuticals (ORMP) Competitors

ORMP vs. IRWD, SVA, CBIO, TECX, and AVTE

How does Oramed Pharmaceuticals compare to Ironwood Pharmaceuticals?

Summary

How does Oramed Pharmaceuticals compare to Sinovac Biotech?

Summary

How does Oramed Pharmaceuticals compare to Crescent Biopharma?

Summary

How does Oramed Pharmaceuticals compare to Tectonic Therapeutic?

Summary

How does Oramed Pharmaceuticals compare to Aerovate Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORMP vs. The Competition

Oramed Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Oramed Pharmaceuticals (ORMP) Competitors

ORMP vs. IRWD, SVA, CBIO, TECX, and AVTE

How does Oramed Pharmaceuticals compare to Ironwood Pharmaceuticals?

Is ORMP or IRWD more profitable?

Do institutionals and insiders have more ownership in ORMP or IRWD?

Which has more risk and volatility, ORMP or IRWD?

Which has better valuation and earnings, ORMP or IRWD?

Does the media prefer ORMP or IRWD?

Do analysts recommend ORMP or IRWD?

Summary

How does Oramed Pharmaceuticals compare to Sinovac Biotech?

Which has better valuation and earnings, ORMP or SVA?

Which has more risk & volatility, ORMP or SVA?

Do institutionals and insiders hold more shares of ORMP or SVA?

Is ORMP or SVA more profitable?

Do analysts rate ORMP or SVA?

Does the media refer more to ORMP or SVA?

Summary

How does Oramed Pharmaceuticals compare to Crescent Biopharma?

Do analysts prefer ORMP or CBIO?

Do institutionals and insiders hold more shares of ORMP or CBIO?

Is ORMP or CBIO more profitable?

Does the media refer more to ORMP or CBIO?

Which has better earnings and valuation, ORMP or CBIO?

Which has more volatility & risk, ORMP or CBIO?

Summary

How does Oramed Pharmaceuticals compare to Tectonic Therapeutic?

Which has stronger earnings & valuation, TECX or ORMP?

Do institutionals & insiders have more ownership in TECX or ORMP?

Which has more risk & volatility, TECX or ORMP?

Does the media prefer TECX or ORMP?

Is TECX or ORMP more profitable?

Do analysts recommend TECX or ORMP?

Summary

How does Oramed Pharmaceuticals compare to Aerovate Therapeutics?

Do analysts rate ORMP or AVTE?

Do insiders & institutionals believe in ORMP or AVTE?

Does the media prefer ORMP or AVTE?

Is ORMP or AVTE more profitable?

Which has stronger valuation and earnings, ORMP or AVTE?

Which has more risk & volatility, ORMP or AVTE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORMP vs. The Competition

Oramed Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools